Future treatment options for HCV: double, triple, what is the optimal combination?
Specifically Targeted Antiviral Therapy against hepatitis C virus (STAT-C) stands for a new era in the treatment of patients with chronic hepatitis C. Results from recent trials with protease and polymerase inhibitors indicate that therapy with a single HCV specific compound will not be sufficient to eradicate hepatitis C virus infection and that combination therapy will be necessary to improve sustained virologic response rates. The search for the optimal combination of STAT-C compounds with peginterferon alfa with or without ribavirin is currently under investigation in several clinical trials. Overall the current studies indicate that peginterferon alfa and ribavirin remain the backbone of antiviral therapy of chronic hepatitis C even in the era of STAT-C. Nevertheless, it can be anticipated that combination of STAT-C compounds with non-overlapping resistance profiles could improve response to antiviral therapy. Promising combinations are protease inhibitors plus nucleoside analogue and non-nucleoside analogue polymerase inhibitors.
Kronenberger
Bernd
B
Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.
Zeuzem
Stefan
S
D000998:Antiviral Agents / Q000008:administration & dosage*; D003562:Cytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D012321:DNA-Directed RNA Polymerases / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000639:trends*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005544:Forecasting; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D009705:Nucleosides / Q000008:administration & dosage; D009842:Oligopeptides / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011355:Prodrugs / Q000008:administration & dosage; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000008:administration & dosage; D011741:Pyrimidine Nucleosides / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009705:Nucleosides; D009842:Oligopeptides; D011355:Prodrugs; D011480:Protease Inhibitors; D011741:Pyrimidine Nucleosides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D003562:Cytidine; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; D012321:DNA-Directed RNA Polymerases; C417083:peginterferon alfa-2b; C506207:valopicitabine; C508950:4'-azidocytidine; C100416:peginterferon alfa-2a; C530825:balapiravir